Enhancing Anti-PD-1 Immunotherapy by Targeting MDSCs via Hepatic Arterial Infusion in Breast Cancer Liver Metastases.

Even though anti-PD-1 therapy as a single agent showed a strong trend toward delaying tumor growth regardless of the anatomic site of the tumor ( Supplementary Figure S5A ), the combination of anti-PD-1 with either CBL0137 HAI or 5FU HAI did not improve survival compared to anti-PD-1 alone in the CT26 model ( Figure 7 A).

also in 5,725 other papers